Transitional month for Specialty Metals’ tungsten operation

Published 01-AUG-2019 12:14 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

The last few months have been a transitional period for Speciality Metals International Limited (ASX:SEI) as the company completed its acquisition of Mt Carbine Quarries Pty Ltd (Mt Carbine Quarries), an entity that owns and operates the Mt Carbine quarry and Mining Leases ML 4867 and ML 4919.

Consequently, the company had plenty of positives to reflect on in its report for the three months to 30 June, 2019, particularly given the group is a near-term tungsten producer.

SEI’s wholly owned subsidiary, Mt Carbine Quarrying Operations Pty Ltd, commenced operating the quarry as of the 1 July 2019 with the handover transitioning smoothly from both an operational and customer perspective.

Aside from the Mt Carbine acquisition, the June quarter saw the commencement of the unincorporated Joint Venture between Speciality Metals and Cronimet Asia Pte Ltd for the development of the Mt Carbine Tungsten Tailings Retreatment and Stockpile Projects.

These events mark the beginning of a new era for Speciality Metals as it now focuses on bringing the Mt Carbine Retreatment Plant back into production with orders for all major components now placed.

The completion and commissioning of this work is still on-schedule to occur during the December quarter of 2019.

Move to production could trigger share price action

Since signing the Cronimet Joint Venture Agreement work on the electrical, pump reconditioning and replacement has commenced, and orders for new equipment have been placed.

Contractors have been engaged to complete the required concrete formwork and remove old equipment surplus to the new plant design.

It is expected much of the upgrade and reconstruction work will be completed in the September quarter.

The company has engaged its environmental consultants to assist with the reactivation of its pre-existing authorities for the recommencement of the Tailings Retreatment and Stockpile Projects.

Significant work has also been completed by the company’s geological team with respect to tenement maintenance and reporting to the relevant government authorities in both Queensland and New South Wales, and this will continue throughout the December half.

Management has previously indicated that the group should be in a position to commence tungsten production in the December quarter of 2019, and as is usually the case with companies approaching production this could provide share price momentum.

Indeed it would appear from the following chart that investors are looking to catch the stock at a relatively cheap price prior to the crucial lead up period to production with the company recently hitting a 12 month high.

SEI could be at a good price on the lead up to production.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free